This is a preview of subscription content, log in via an institution to check access.
References
Bryson HM, Sorkin EM. Cladribine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs 1993 Nov; 46: 872–94
Cladribine and pentostatin improve the outlook in hairy cell leukaemia. Drugs Ther Perspect 1994 Feb 21; 3(3): 4–7
Langtry HD, Lamb HM. Cladribine: a review of its use in multiple sclerosis. BioDrugs 1998 May; 9(5): 419–33
Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A 1996 Feb 20; 93: 1716–20
Rice G, Cladribine Study Group. Cladribine and chronic progressive multiple sclerosis: the results of a multicenter trial [abstract]. Neurology 1997 Jun; 48: 1730
Grieb P, Ryba M, Stelmasiak Z, et al. Cladribine treatment of multiple sclerosis [letter]. Lancet 1994 Aug 20; 344: 538
Glatiramer acetate: promise in relapsing-remitting multiple sclerosis. Drugs Ther Perspect 1998 May 25; 11(10): 1–5
Hauser SL. Multiple sclerosis and other demyelinating diseases. In: Isselbacher KJ, Braunwald E, Wilson JD, et al. editors. Harrison’s principles of internal medicine. Vol 2. 13th ed. New York: McGraw-Hill Inc., 1994: 2287–95
Rights and permissions
About this article
Cite this article
Cladribine has potential in multiple sclerosis, but is not without toxicity. Drugs Ther. Perspect 12, 1–4 (1998). https://doi.org/10.2165/00042310-199812120-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199812120-00001